← Back to Screener
Immunome, Inc. (IMNM)
Price$24.25
Favorite Metrics
Price vs S&P 500 (26W)68.19%
Price vs S&P 500 (4W)13.60%
Market Capitalization$2.79B
All Metrics
Book Value / Share (Quarterly)$5.61
P/TBV (Annual)20.53x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.83
Price vs S&P 500 (YTD)10.53%
Net Profit Margin (TTM)-1687.08%
EPS (TTM)$-2.41
10-Day Avg Trading Volume1.04M
EPS Excl Extra (TTM)$-2.41
EPS (Annual)$-2.43
ROI (Annual)-33.48%
Cash / Share (Quarterly)$5.78
ROA (Last FY)-31.09%
Revenue Growth TTM (YoY)-23.23%
EBITD / Share (TTM)$-2.54
ROE (5Y Avg)-111.44%
Operating Margin (TTM)-1784.14%
Cash Flow / Share (Annual)$-1.83
P/B Ratio4.39x
P/B Ratio (Quarterly)3.74x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)169.43x
Net Interest Coverage (TTM)-2470.00x
ROA (TTM)-52.39%
EPS Incl Extra (Annual)$-2.43
Current Ratio (Annual)14.69x
Quick Ratio (Quarterly)14.53x
3-Month Avg Trading Volume1.85M
52-Week Price Return243.51%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.50
P/S Ratio (Annual)401.45x
Asset Turnover (Annual)0.01x
52-Week High$27.65
EPS Excl Extra (Annual)$-2.43
CapEx CAGR (5Y)93.32%
26-Week Price Return76.94%
Quick Ratio (Annual)14.53x
13-Week Price Return18.64%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)14.69x
Enterprise Value$2,132.989
Asset Turnover (TTM)0.04x
Book Value / Share Growth (5Y)7.59%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-3059.99%
Cash / Share (Annual)$5.78
3-Month Return Std Dev59.11%
Net Income / Employee (TTM)$-2
ROE (Last FY)-33.48%
Net Interest Coverage (Annual)-784.00x
EPS Basic Excl Extra (Annual)$-2.43
P/FCF (TTM)128.80x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.41
ROI (TTM)-57.61%
P/S Ratio (TTM)221.34x
Revenue / Share (Annual)$0.08
Tangible BV / Share (Annual)$1.37
Price vs S&P 500 (52W)208.42%
Year-to-Date Return14.66%
5-Day Price Return8.89%
EPS Normalized (Annual)$-2.43
ROA (5Y Avg)-84.20%
Net Profit Margin (Annual)-3059.99%
Month-to-Date Return12.62%
Cash Flow / Share (TTM)$-1.77
EBITD / Share (Annual)$-2.54
Operating Margin (Annual)-3228.83%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-111.44%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.41
P/TBV (Quarterly)56.26x
P/B Ratio (Annual)3.74x
Pretax Margin (TTM)-1687.08%
Book Value / Share (Annual)$5.61
Price vs S&P 500 (13W)15.78%
Beta2.19x
Revenue / Share (TTM)$0.07
ROE (TTM)-57.61%
52-Week Low$6.96
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.26
4.26
4.25
4.25
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
IMNMImmunome, Inc. | 221.34x | -23.23% | — | — | $24.25 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Immunome Inc is a targeted oncology company advancing antibody-drug conjugates and radioligand therapies. Its lead program, varegacestat, demonstrated positive Phase 3 results in desmoid tumors, with additional programs including the Phase 1-stage ROR1 ADC IM-1021 and IND-cleared FAP-targeted radioligand IM-3050. The company maintains a preclinical portfolio of solid tumor ADCs.